Earnings season is upon us; Makary on rare disease; Startup is first to...
Welcome back to Endpoints Weekly! Our team of reporters covered first-quarter earnings results from a handful of companies this week. See below for pharma executives’ comments on tariff exposure,...
View ArticleJ&J reports durability data for bladder cancer 'pretzel' drug
Johnson & Johnson said its drug-device combo for bladder cancer achieved a high rate of complete responses lasting at least a year, according to the latest data cut from a registrational trial....
View Article#AACR25: Revolution’s KRAS drug shows potential in early cut of lung cancer data
CHICAGO — An experimental KRAS G12D drug from Revolution Medicines made waves last year as a potential treatment for pancreatic cancer. On Sunday, new results from an early data readout showed it works...
View Article#AACR25: Keytruda around head and neck cancer surgery cuts chance of disease...
CHICAGO — Merck’s widely used cancer drug Keytruda could soon be getting another indication, this time for use before and after surgery for head and neck cancer. On Sunday, data presented from the...
View Article#AACR25: GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer
GSK’s Jemperli has maintained its outstanding efficacy among patients with a particular form of rectal cancer. Every one of 49 patients with mismatch repair deficient (MMRd) rectal tumors in a...
View ArticleExclusive: Axiom raises $15M to build AI models for drug toxicity
Brandon White started his career like a Silicon Valley stereotype — as a 20-year-old who skipped college to join Uber’s machine learning team in 2014. But White soon found himself unhappy and...
View ArticleFrance stops Valneva's chikungunya vaccine rollout in over 65s after safety...
France’s national public health agency is suspending immunization of adults 65 years and older with Valneva’s chikungunya vaccine Ixchiq after three patients were hospitalized, including one who died....
View ArticleEuropean regulators recommend new drugs from Vertex, Amgen and Jazz
Vertex Pharmaceuticals, Amgen and Jazz Pharmaceuticals are among companies that received a positive opinion from European regulators for drugs that are already in the US market. The European Medicines...
View ArticleMerck KGaA to buy rare cancer biotech SpringWorks for $3.9B
Merck KGaA said Monday it has inked a “definitive agreement” to acquire Pfizer spinout SpringWorks Therapeutics for an equity value of around $3.9 billion, rounding off several months of negotiations....
View Article#AACR25: Boehringer’s updated results in HER2-mutated lung cancer impress
CHICAGO — Boehringer Ingelheim’s targeted lung cancer drug led to durable responses, according to the latest data from the early-stage trial. The German drugmaker is studying zongertinib in lung cancer...
View ArticleDaiichi Sankyo says production boost in US will help cushion tariff impact
Daiichi Sankyo has reiterated that its earlier plans to expand ADC manufacturing in the US, including for its blockbuster drug Enhertu, will help alleviate some pressure from President Donald Trump's...
View ArticleScholar Rock names new CEO, adds biotech veterans in C-suite rebuild
As it awaits an FDA approval decision, Scholar Rock is reshaping its leadership team with industry veterans. Current CEO Jay Backstrom is departing the Cambridge, MA-based drug developer in a "planned...
View ArticleBiohaven gets an up to $600M investment; Prilenia, Ferrer make a deal in Europe
Plus, #AUA2025 news from Protara Therapeutics, Pfizer, CG Oncology, and UroGen, in addition to the latest updates from Spruce Biosciences and Rezolute: Biohaven’s up to $600M financing deal: The...
View ArticleWuXi AppTec sees revenue growth after 2024’s decline
WuXi AppTec’s revenue rose for the first few months of 2025, signaling that pressures from the proposed Biosecure Act may be subsiding even as the threat of pharma tariffs remains. The CDMO pulled in...
View ArticleNovavax responds to FDA's request for new Covid vaccine trial
Novavax said it's responded to the FDA's request for a new clinical trial post-approval of the company's Covid-19 vaccine, following a report that the agency asked for a randomized study that could...
View ArticleBill cutting tax deductions for drug ads could help fund 'pill penalty' fix
A bipartisan piece of legislation proposed this week would prohibit pharma companies from receiving tax deductions for direct-to-consumer drug advertising, a bill that could generate savings to offset...
View ArticleVaxart says stop-work order was lifted on next-gen Covid vaccine
Vaxart said a stop-work order has been lifted on its next-generation Covid-19 vaccine efforts planned under a Biden-era initiative, allowing it to screen participants for a large mid-stage trial to...
View ArticleOctagon Therapeutics shuts down after 'unresolved biology questions'
Octagon Therapeutics is winding down operations, its CEO posted on LinkedIn on Monday. The biotech, with operations in Cambridge, MA, and Providence, RI, had been working on programs in autoimmune and ...
View ArticleFDA delays decision date for small biotech, raising questions about impact of...
The fate of a small, privately-held biotech’s new drug has been delayed, in what appears to be a sign that broad cuts to the FDA by the Trump administration may be affecting key regulatory decisions ...
View ArticleNovartis Q1 earnings: Company raises 2025 bar after beating sales expectations
Novartis is starting the year on a strong note as several of its core medicines beat Wall Street’s sales projections, prompting the drugmaker to shift its full-year guidance to a higher bar. In the...
View Article